Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: BHC stock price vs MU: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MU's multiple
Needs MU P/E.
Implied fair value · at BHC's multiple
Needs BHC P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BHC FY 2025 (ended Dec 31, 2025) · MU FY 2025 (ended Aug 28, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Bausch Health Companies Inc. · implied price per share
Bear
$39.97
Base
$47.02
Bull
$54.08
Micron Technology, Inc. · implied price per share
Bear
$120.98
Base
$142.33
Bull
$163.68
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
-37.98x
0.27x
Net debt / EBITDA
Leverage against operating earnings
4.54x
0.25x
Cash and equivalents
Liquid reserves on the balance sheet
$1.32B
$9.94B
Total debt
Interest-bearing obligations outstanding
$21.04B
$14.58B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AbbVie Inc.
BHC vs ABBV
Organon & Co.
BHC vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
BHC vs TEVA
SUPERNUS PHARMACEUTICALS, INC.
BHC vs SUPN
ANI PHARMACEUTICALS INC
BHC vs ANIP
WESTERN DIGITAL CORP
BHC vs WDC
Seagate Technology Holdings plc
BHC vs STX
INTEL CORP
BHC vs INTC
NVIDIA CORP
BHC vs NVDA
Broadcom Inc.
BHC vs AVGO
TEXAS INSTRUMENTS INC
BHC vs TXN
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe BHC can sustain its 6.7% revenue growth while improving margins and avoiding balance-sheet stress, then BHC may be attractive as a deep-value turnaround because it trades near the bottom of its historical range and far below the provided MU-implied and DCF values.
On a P/E basis, BHC’s current price of $4.90 is far below the MU MU-implied price of $53.98, implying 1001.7% upside, but that gap is not directly comparable given MU’s far higher earnings multiple and growth profile. BHC also sits near the low end of its historical band, suggesting the stock already reflects elevated distress/quality risk.
Supporting Metrics
